AR101728A1 - Formulación de liberación plurimodal de doxilamina y piridoxina y/o metabolitos o sales de las mismas - Google Patents
Formulación de liberación plurimodal de doxilamina y piridoxina y/o metabolitos o sales de las mismasInfo
- Publication number
- AR101728A1 AR101728A1 ARP150102789A ARP150102789A AR101728A1 AR 101728 A1 AR101728 A1 AR 101728A1 AR P150102789 A ARP150102789 A AR P150102789A AR P150102789 A ARP150102789 A AR P150102789A AR 101728 A1 AR101728 A1 AR 101728A1
- Authority
- AR
- Argentina
- Prior art keywords
- doxylamine
- component
- active ingredient
- piridoxine
- metabolites
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Forma de dosificación oral sólida que comprende un núcleo que comprende un componente de doxilamina y un componente de piridoxina revestido con un revestimiento entérico. La forma de dosificación oral sólida comprende además dos revestimientos que contienen ingrediente activo que rodean el revestimiento entérico, los revestimientos que contienen ingrediente activo se separan uno del otro por un revestimiento intermedio, y uno de los dos revestimientos contiene ingrediente activo que comprende un componente de doxilamina y está libre de un componente de piridoxina, y el otro de los dos revestimientos contiene ingrediente activo que comprende un componente de piridoxina y está libre de componente de doxilamina. Usos de la forma de dosificación oral sólida para el alivio de los síntomas de náuseas y vómito, por ejemplo en el caso de náuseas y vómito del embarazo (NVP).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CA2014/050828 WO2016029290A1 (en) | 2014-08-29 | 2014-08-29 | Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR101728A1 true AR101728A1 (es) | 2017-01-11 |
Family
ID=55398524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150102789A AR101728A1 (es) | 2014-08-29 | 2015-08-31 | Formulación de liberación plurimodal de doxilamina y piridoxina y/o metabolitos o sales de las mismas |
Country Status (26)
| Country | Link |
|---|---|
| EP (1) | EP3185856B1 (es) |
| JP (1) | JP6272561B2 (es) |
| KR (1) | KR101831570B1 (es) |
| CN (1) | CN106794148B (es) |
| AR (1) | AR101728A1 (es) |
| AU (1) | AU2014405049B2 (es) |
| CA (1) | CA2920247C (es) |
| CY (1) | CY1120788T1 (es) |
| DK (1) | DK3185856T3 (es) |
| EA (1) | EA032671B1 (es) |
| ES (1) | ES2674996T3 (es) |
| FR (1) | FR24C1000I1 (es) |
| HU (1) | HUE038969T2 (es) |
| IL (1) | IL250541B (es) |
| LU (1) | LUC00356I2 (es) |
| MX (1) | MX360662B (es) |
| MY (1) | MY196073A (es) |
| PH (1) | PH12017500282A1 (es) |
| PL (1) | PL3185856T3 (es) |
| PT (1) | PT3185856T (es) |
| SA (1) | SA517380942B1 (es) |
| SG (1) | SG11201701448XA (es) |
| TR (1) | TR201809565T4 (es) |
| UA (1) | UA118711C2 (es) |
| WO (1) | WO2016029290A1 (es) |
| ZA (1) | ZA201701063B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS61368B1 (sr) * | 2018-09-27 | 2021-02-26 | Inibsa Ginecologia S A | Postupak za pripremu višejediničnog oralnog doznog oblika sa modifikovanim oslobađanjem doksilamin sukcinata i piridoksin hidrohlorida |
| AR121619A1 (es) * | 2020-03-25 | 2022-06-22 | Inibsa Ginecologia S A | Una forma de dosificación oral de múltiples unidades de liberación modificada de succinato de doxilamina y clorhidrato de piridoxina y un procedimiento para su preparación |
| AR132739A1 (es) | 2023-05-22 | 2025-07-23 | Italfarmaco Spa | Una forma de dosificación oral de unidades múltiples de succinato de doxilamina y clorhidrato de piridoxina sin dióxido de titanio |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2772615B1 (fr) * | 1997-12-23 | 2002-06-14 | Lipha | Comprime multicouche pour la liberation instantanee puis prolongee de substances actives |
| CA2350195C (en) | 2000-12-20 | 2003-06-10 | Duchesnay Inc. | Rapid onset formulation of pyridoxine hydrochloride and doxylamine succinate |
| TWI292138B (en) * | 2004-03-11 | 2008-01-01 | Mstar Semiconductor Inc | Device for adaptively adjusting video's luminance and related method |
| PL1814527T5 (pl) * | 2004-11-05 | 2021-08-02 | Boehringer Ingelheim International Gmbh | Dwuwarstwowa tabletka zawierająca telmisartan i amlodypinę |
| CN102348452A (zh) * | 2009-03-20 | 2012-02-08 | 诺瓦提斯公司 | 缬沙坦和阿利吉仑的固定剂量组合的盖仑制剂 |
| EP2500016A1 (en) * | 2011-03-18 | 2012-09-19 | Laboratorios Del. Dr. Esteve, S.A. | Doxylamine resinate complex |
| CA2761212A1 (en) * | 2011-12-07 | 2013-06-07 | Pharmascience Inc. | Disintegrant-free delayed release doxylamine and pyridoxine formulation and process of it manufacturing |
| WO2013123569A1 (en) * | 2012-02-22 | 2013-08-29 | Duchesnay Inc. | Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof |
| JP5914701B2 (ja) * | 2012-02-22 | 2016-05-11 | デュシネイ・インコーポレイテッド | ドキシラミンおよびピリドキシン、ならびに／またはその代謝物もしくは塩の製剤 |
-
2014
- 2014-08-29 SG SG11201701448XA patent/SG11201701448XA/en unknown
- 2014-08-29 KR KR1020177008120A patent/KR101831570B1/ko active Active
- 2014-08-29 HU HUE14900963A patent/HUE038969T2/hu unknown
- 2014-08-29 UA UAA201702935A patent/UA118711C2/uk unknown
- 2014-08-29 CN CN201480081512.3A patent/CN106794148B/zh active Active
- 2014-08-29 CA CA2920247A patent/CA2920247C/en active Active
- 2014-08-29 EA EA201790477A patent/EA032671B1/ru unknown
- 2014-08-29 MX MX2017002495A patent/MX360662B/es active IP Right Grant
- 2014-08-29 PT PT14900963T patent/PT3185856T/pt unknown
- 2014-08-29 WO PCT/CA2014/050828 patent/WO2016029290A1/en not_active Ceased
- 2014-08-29 DK DK14900963.1T patent/DK3185856T3/en active
- 2014-08-29 ES ES14900963.1T patent/ES2674996T3/es active Active
- 2014-08-29 PL PL14900963T patent/PL3185856T3/pl unknown
- 2014-08-29 JP JP2017511764A patent/JP6272561B2/ja active Active
- 2014-08-29 TR TR2018/09565T patent/TR201809565T4/tr unknown
- 2014-08-29 AU AU2014405049A patent/AU2014405049B2/en active Active
- 2014-08-29 MY MYPI2017700682A patent/MY196073A/en unknown
- 2014-08-29 EP EP14900963.1A patent/EP3185856B1/en active Active
-
2015
- 2015-08-31 AR ARP150102789A patent/AR101728A1/es not_active Application Discontinuation
-
2017
- 2017-02-09 IL IL250541A patent/IL250541B/en active IP Right Grant
- 2017-02-13 ZA ZA201701063A patent/ZA201701063B/en unknown
- 2017-02-15 PH PH12017500282A patent/PH12017500282A1/en unknown
- 2017-02-21 SA SA517380942A patent/SA517380942B1/ar unknown
-
2018
- 2018-08-10 CY CY20181100842T patent/CY1120788T1/el unknown
-
2024
- 2024-01-04 FR FR24C1000C patent/FR24C1000I1/fr active Active
- 2024-08-05 LU LU00356C patent/LUC00356I2/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2020000102A (es) | Compuestos útiles para inhibir a cdk7 | |
| IL254353B (en) | Vaporizer capsule for vaporising an active ingredient | |
| CL2018002334A1 (es) | Moduladores de complementos factor b (divisional solicitud 201600606) | |
| BR112017007123A2 (pt) | derivados de tetrahidroisoquinolina | |
| ECSP18040250A (es) | Composiciones y métodos para inhibir la actividad arginasa | |
| MX2017001512A (es) | Compuestos activos hacia bromodominios. | |
| BR112018010720A8 (pt) | agonistas do receptor de apelina e métodos de uso | |
| UY36275A (es) | Compuestos aminopirimidinilo | |
| BR112016024631A2 (pt) | cápsulas antimicrobianas para conectores médicos | |
| SV2016005137A (es) | Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos | |
| MX356181B (es) | Sistemas y bandejas de manejo de fibras y dispositivos de interfaz de red que incorporan tales sistemas y bandejas. | |
| BR112016024057A2 (pt) | inibidores de quinases heterocíclicos | |
| CR20180564A (es) | Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que lo contienen | |
| GT201700023A (es) | Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias | |
| MX2018015985A (es) | Composiciones, dispositivos y metodos para el tratamiento del trastorno relacionado con el consumo de alcohol. | |
| DK3582780T3 (da) | Aminopyrimidinforbindelser, der er anvendelige som SSAO-inhibitorer | |
| CR20160192A (es) | Formulación de farmaco de liberación retardada | |
| BR112016024539A8 (pt) | Combinador óptico ativo para rede catv | |
| BR112018074655A2 (pt) | formulação injetável de fosnetupitant e método de fabricação de uma formulação | |
| CR20180089A (es) | Compuestos útiles para inhibir a ror-gamma-t | |
| BR112018070615A2 (pt) | formulação em grânulos contendo cloridrato de cariprazina para administração oral. | |
| MX2017002495A (es) | Formulacion de liberacion plurimodal de doxilamina y piridoxina y/o metabolitos o sales de las mismas. | |
| EP4069214C0 (en) | POLYPHOSPHAZENE-BASED DRUG CARRIERS | |
| MX384637B (es) | Compuestos oxadiazoespíricos para el tratamiento del abuso y la adicción a las drogas. | |
| MX2020004202A (es) | Fenil sulfonil fenil triazol tionas sustituidas y usos de las mismas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |